OncoZenge: Back on track - Redeye

Redeye initiates coverage of OncoZenge, a Swedish biotech company offering an innovative solution to the USD1.6bn oral mucositis treatment market. Bolstered by a strong ownership, a newly signed commercial partnership, and a de-risked pathway to the market, we see ample upside potential.

Länk till analysen i sin helhet: https://www.redeye.se/research/1049948/oncozenge-back-on-track?utm_source=finwire&utm_medium=RSS